Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.
GlycoNet researchers develop new chemical biological tools to monitor Parkinson’s disease
Researchers are a step closer to understanding how Parkinson’s disease develops and progresses.
GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
Engagement and collaboration in action at the 2022 Canadian Glycomics Symposium
Read some highlights from the 2022 Canadian Glycomics Symposium.
Enzymes linked with immune cell activity could hold key to better understanding inflammation
Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
Glycomics is writing the next chapter in bioinnovation
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.
7 tips for creating a scientific poster
Linkedin-in Twitter Facebook-f Instagram Youtube Envelope
GlycoNet and partners invest $7.7 million in Canadian health innovation
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.
English 
French